AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States
On May 31, 2022, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group (“AOP Health”), applied to the U.S. Food and Drug Administration (FDA) for approval of its beta blocker landiolol – another step in the Company’s expansion in the United...
Zur Pressemeldung auf www.aoporphan.com